Renal concentration capacity in primary hyperparathyroidism

Aim. To evaluate the renal concentration capacity in patients with mild and severe primary hyperparathyroidism (pHPT).

Materials and methods. The study included 77 patients (median age 57 years [52;61]) with pHPT, first group was comprised of patients with mild form (n=23), second group contained patients with severe pHPT without nephrolithiasis (n=28) and the third group contained patients with pHPT and nephrolithiasis (n=26). Osmolality index was calculated as urine osmolality to blood osmolality ratio. Renal concentration capacity impairment was diagnosed with osmolality index less than 2.

Results. Osmolality index in patients with pHPT was low with median 1,66 [1,38;2,1]. We found a high prevalence of renal concentration capacity impairment in patients with pHPT, that was 71,4%. Regardless of presence of nephrolithiasis both patients with mild and severe pHPT had similar prevalence (70%, 75% and 69,2% respectively).

Conclusions. Renal concentration impairment is common in mild and severe pHPT. The findings of this study necessitate for measurement of urine osmolality or osmolality index in all patients with pHPT.Комбинированную терапию ожирения (диета, физические нагрузки + прием орлистата) в течение 7 ± 1 месяцев получали 15 пациентов первой группы (СОАС), 5 – во второй (инсомния) и 8 пациентов без нарушений сна. При сравнении групп не выявлено статистически значимых различий по числу пациентов, принимающих медикаментозную терапию ожирения           (р < 0,05). Через 7 ± 1 месяцев лечения ожирения среднее снижение МТ у больных с синдромом инсомнии составило –2,5 [–4; 0] кг, у больных с СОАС –7 [–18; –2] кг, у пациентов без нарушений сна –6,5 [–12;  –2,25] кг. 

1. Pyram R, Mahajan G, Gliwa A. Primary hyperparathyroidism: Skeletal and nonskeletal effects, diagnosis and management. Maturitas. 2011;70(3):246-55. doi:10.1016/j.maturitas.2011.07.021

2. Lila A, Sarathi V, Jagtap V, Bandgar T, Menon P, Shah N. Renal manifestations of primary hyperparathyroidism. Indian Journal of Endocrinology and Metabolism. 2012;16(2):258. doi:10.4103/2230-8210.93745

3. Adami S, Marcocci C, Gatti D. Epidemiology of primary hyperparathyroidism in Europe. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research. 2002;17:N18-23.

4. Bardin T, editor [Primary hyperparathyroidism. Clinical, epidemiological and histological aspects]. Annales d'endocrinologie; 1993.

5. Wermers RA, Khosla S, Atkinson EJ, Achenbach SJ, Oberg AL, Grant CS, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993–2001: an update on the changing epidemiology of the disease. Journal of Bone and Mineral Research. 2006;21(1):171-7.

6. Yu N, Donnan PT, Murphy MJ, Leese GP. Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK. Clinical Endocrinology. 2009;71(4):485-93. doi:10.1111/j.1365-2265.2008.03520.x

7. Bilezikian JP. Clinical spectrum of PHPT. Reviews in Endocrine and Metabolic Disorders. 2000;1(4):237-45. doi:10.1023/a:1026508829397

8. Silverberg SJ, Walker MD, Bilezikian JP. Asymptomatic Primary Hyperparathyroidism. Journal of Clinical Densitometry. 2013;16(1):14-21. doi:10.1016/j.jocd.2012.11.005

9. Mokrysheva N. G., Рожинская Л.Я., Перетокина Е.В., Ростомян Л.Г. и соавт. Анализ основных эпидемиологических характеристик первичного гиперпаратиреоза в России (по данным регистра) //Проблемы Эндокринологии. – 2012. – Т. 58. – №. 5. – С. 16-20.[Mokrysheva NG, Rozhinskaia LI, Peretokina EV, Rostomian LG, Mirnaia SS, Pronin VS, et al. The results of analysis of the major epidemiological characteristics of primary hyperparathyroidism in Russia based on the registry data. Problemy Endokrinologii. 2012;58(5):16-20] doi: 10.14341/probl201258516-20

10. Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, et al. Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Fourth International Workshop. The Journal of Clinical Endocrinology & Metabolism. 2014;99(10):3561-9. doi:10.1210/jc.2014-1413

11. Hedback, Oden. Death risk factor analysis in primary hyperparathyroidism. European Journal of Clinical Investigation. 1998;28(12):1011-8. doi:10.1046/j.1365-2362.1998.00387.x

12. Hedback G, Abrahamsson K, Oden A. The improvement of renal concentration capacity after surgery for primary hyperparathyroidism. European Journal of Clinical Investigation. 2001;31(12):1048-53. doi:10.1046/j.1365-2362.2001.00926.x

13. Marx SJ, Attie MF, Stock JL, Spiegel AM, Levine MA. Maximal Urine- Concentrating Ability: Familial Hypocalciuric HypercalcemiaVersusTypical Primary Hyperparathyroidism. The Journal of Clinical Endocrinology & Metabolism. 1981;52(4):736-40. doi:10.1210/jcem-52-4-736

14. Jansson S, Morgan E. Biochemical Effects from Treatment with Bisphosphonate and Surgery in Patients with Primary Hyperparathyroidism. World Journal of Surgery. 2004;28(12):1293-7. doi:10.1007/s00268-004-7611-1

15. van 't Hoff W, Bicknell EJ. Renal tubular function in hyperparathyroidism. Postgraduate Medical Journal. 1989;65(769):811-3. doi:10.1136/pgmj.65.769.811

16. Bilezikian JP, Khan AA, Potts JT. Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Third International Workshop. The Journal of Clinical Endocrinology & Metabolism. 2009;94(2):335-9. doi:10.1210/jc.2008-1763

17. Кишкун А. А. Руководство по лабораторным методам диагностики. – М.: Гэотар-медиа; 2013.[Kishkun A. A. Rukovodstvo po laboratornym metodam diagnostiki. Moscow: Geotar-media; 2013. (In Russ).]

18. Моисеев В. С. и др. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио-нефропротекции //Российский кардиологический журнал. – 2014. – №. 8. – С. 7-37. [Moiseev VS, Mukhin NA, Smirnov AV, Kobalava ZhD et al. Serdechno-sosudistyy risk i khronicheskaya bolezn' pochek: strategii kardionefroprotektsii. Rossiyskiy kardiologicheskiy zhurnal. 2014(8):7-37.]